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Abstract
Background: What currently appears to be irreversible axonal loss in normal appearing white
matter, measured by proton magnetic resonance spectroscopy is of great interest in the study of
Multiple Sclerosis. Our aim is to determine the axonal damage in normal appearing white matter
measured by magnetic resonance spectroscopy and to correlate this with the functional disability
measured by Multiple Sclerosis Functional Composite scale, Neurological Rating Scale, Ambulation
Index scale, and Expanded Disability Scale Score.
Methods: Thirty one patients (9 male and 22 female) with relapsing remitting Multiple Sclerosis
and a Kurtzke Expanded Disability Scale Score of 0–5.5 were recruited from four hospitals in
Andalusia, Spain and included in the study. Magnetic resonance spectroscopy scans and neurological
disability assessments were performed the same day.
Results: A statistically significant correlation was found (r = -0.38 p < 0.05) between disability
(measured by Expanded Disability Scale Score) and N-Acetyl Aspartate (NAA/Cr ratio) levels in
normal appearing white matter in these patients. No correlation was found between the NAA/Cr
ratio and disability measured by any of the other disability assessment scales.
Conclusions: There is correlation between disability (measured by Expanded Disability Scale
Score) and the NAA/Cr ratio in normal appearing white matter. The lack of correlation between
the NAA/Cr ratio and the Multiple Sclerosis Functional Composite score indicates that the Multiple
Sclerosis Functional Composite is not able to measure irreversible disability and would be more
useful as a marker in stages where axonal damage is not a predominant factor.
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Multiple sclerosis (MS) is a chronic disease of the central
nervous system characterised by multicentral inflamma-
tion and myelin destruction. Although axonal pathology
in Multiple Sclerosis (MS) has been recognized since the
initial description of Charcot [1], emphasis generally has
been placed on the relative sparing of axons in traversing
lesions. Recent pathology studies [2-5] have stressed the
importance of axonal pathology in MS, in addition to
demyelination, in lesions and in Normal Appearing
White Matter (NAWM).
Magnetic resonance imaging (MRI) is now widely used for
diagnosing MS and detecting clinically silent lesions in
clinical trials on MS treatment. However, correlations
found between conventional techniques, such as T2-
weighted lesion load, and disability, are weak or absent
[6-8] and therefore, neither the magnetic resonance tech-
niques used so far nor clinical measurements are gold
standard to assess disease or disability, in vivo. This
reflects the inability of conventional MRI to accurately
depict the pathology of MS as regards to histopathologic
heterogeneity of MS lesions and the pathological proc-
esses occurring in the NAWM [9]. These limitations may
account for the weak correlation between disability and
MRI findings in patients with MS.
Clinical measurements used so far lack the accuracy to
demonstrate small changes, show only moderate repro-
ducibility and therefore do not fulfil requirements for
being reliable outcome assessment measures [10-12]
Assessment of clinical disability began to improve with
use of the Multiple Sclerosis Functional Composite
(MSFC). This scale has some advantages over the
Expanded Disability Status Scale (EDSS) [13] as it is a
more sensitive and reproducible outcome measure, and
covers more independent neurological domains [14-16].
In addition MSFC correlates better than EDSS with T1 and
T2 weighted lesion volume (LV) [16].
Alteration of NAWM is of great importance because its
true patho-physiological significance is not completely
understood. Decrease in N-Acetyl Aspartate (NAA) has
been used as an marker of axonal damage or loss that pre-
sumably appears secondary to inflammation or demyeli-
nation [5,17], although primary axonal damage is not
excluded [3]. The limitation of T2-weighted MRI, in delin-
eating tissue damage occurring in CNS, can be partially
overcome by the use of other MR modalities as hypoin-
tense lesions load of T1-weighted images [18,19], Magnet-
ization Transfer Imaging (MTI), Diffusion Tensor Imaging
(DTI) [20-24], and Proton Magnetic Resonance Spectros-
copy (H-MRS).
Proton magnetic resonance spectroscopy (H-MRS) is a
technique that has the potential to detect axonal loss non-
invasively. The normal proton spectrum is dominated by
N-acetyl derived groups (NA). The predominant compo-
nent of the NA peak is N-acetyl aspartate (NAA) [25], an
amino acid metabolite which has been shown to be con-
tained almost exclusively within neurons [26]. A loss of
neurons would thus predict a persistent reduction in the
levels of NAA. Such a reduction has been reproducibly
demonstrated in several diseases characterised by neuro-
nal loss [27-29]. There are now many studies in the litera-
ture that report a reduction of NAA from acute lesions [30-
33], in chronic multiple sclerosis lesions [30-34], in areas
of normal appearing white matter [32,35,36], and form
grey matter [37-40]. Furthermore, the degree of NAA
reduction seems to be most marked in those patient
groups with greatest neurological disability [41-43].
In this study we focus on the axonal loss in NAWM meas-
ured by H-MRS and attempt to determine a correlation
between this damage and the functional disability meas-
ured by Multiple Sclerosis Functional Composite scale
(MSFC) [44], Neurological Rating Scale (NRS) [45],
Ambulation Index scale (AI), and Expanded Disability
Scale Score (EDSS) [13].
Methods
Population studied
A total of 31 patients (9 male and 22 female) diagnosed
with MS according to Poser [46] criteria and who had had
at least two episodes in the previous two years, were
included in the study. Patients were from four hospitals in
Andalusia, Spain (Hospital Universitario Virgen
Macarena, Seville; Hospital Puerta del Mar, Cádiz; Hospi-
tal San Cecilio, Granada; and Hospital Ciudad de Jaén,
Jaén). These patients had been previously diagnosed with
RRMS [47] and had an EDSS of 0 to 5.5 as an inclusion cri-
teria. None of the patients had been previously treated
with an immunosuppressive agent or an immunomodu-
lating agent or corticosteroids within the previous month.
Prior to H-MRS examination each patient's disability was
measured using MSFC scale [44], NRS [45], AI scale and
EDSS [13]. The H-MRS was performed the same day as the
neurological examination by the same neuroradiologist at
the same center using the same MRI scanner and follow-
ing the same protocol. The neuroradiologist was blinded
to the neurological examination results and all the neurol-
ogists were blinded to the MRS results.
This was a multicentre, cross-sectional study within an
ongoing prospective, longitudinal study. The study was
approved by the Ethics Committees of the participating
hospitals and informed consent was obtained from all the
patients.Page 2 of 10
(page number not for citation purposes)
BMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/8At the beginning of the study MRI and H-MRS were also
performed on 10 healthy, age matched control subjects
with not known systemic or neurological disease by the
same neuroradiologist using the same MRI scanner and
following the same protocol as well.
Magnetic resonance measurements
H-MRS and conventional MRI examinations of the brain
were obtained in a single session for each patient using
the same 1.5 T scanner (Signa Horizon, GE, Mass).
In the conventional MRI examinations a sagittal T2
weighted sequence (TR = 4000; TE = 109; slice thickness =
4 mm; gap = 1 mm; 13 slices) was acquired. These slices
were used to obtain transverse and coronal proton density
weighted and T2 weighted images (TR = 3420; TE = 13.5/
121; slice thickness = 5 mm; gap = 2 mm; 30 slices) and a
coronal T1 weighted sequence (TR = 400; TE = 15; slice
thickness = 5 mm.; gap = 2 mm; 15 slices).
These conventional MR images were used to position a
spectroscopic volume of interest (VOI) in one or two areas
with demyelinating lesions and one area of normal
appearing white matter in MS patients and in one area of
normal white matter in the healthy control group. Spec-
troscopy volume selection was performed using a PROBE-
P sequence (PROBE/SV: PROton Brain Examination/Sin-
gle Volume), a version of the PRESS sequence (Point
Resolved Spectroscopy), which is a double spin echo that
uses a 90°-180°-180° pulse sequence to acquire the pro-
ton spectra (TR = 2000; TE = 37; field of vision = 22 × 16
cm). Each VOI measured 20 mm anteroposterior × 20 mm
craneocaudal × 20 mm left-right, obtaining a brain tissue
volume of 8 cc. (see Figure 1) VOIs were selected manu-
ally by the only neuroradiologist of the study (P.P.) and
they were kept constant in size and position in the follow
up examinations. Magnetic field homogeneity was opti-
mized to a line width of about 5 Hz over the VOI using the
proton signal from water. Water suppression was achieved
by a selective inversion of the water resonance prior to
volume selection using adiabatic inversion pulse and
adjustment of the waiting time so that the spectrum was
acquired when the water signal passed through zero.
Clinical assessments
MS patients were examined to determine, the same day,
their EDSS [13], Neurological Rating Scale [45], Ambula-
tion Index, 25 foot timed walk test (TWT) [14], nine hole
peg test (9 HPT) [48], and paced auditory serial addition
test (PASAT 3 s interval) [49] scores. The average of two
trials for the TWT and average of four trials of the 9 HPT
[44] were calculated and, together with PASAT and Multi-
ple Sclerosis Functional Composite (MSFC) [44] scores
were used in further analyses. All neurologists are trained
to use Kurtzke's scale, AI scale, NRS, and MSFC scale, but
they were retrained to use these scales by the same person
and on the same day.
Statistical analysis
Data was entered into the SAS programme and a descrip-
tive and analytical statistical analysis was carried out.
Absolute frequencies and percentages were used for the
description of the categorical variables using the SAS/
BASE PROC TABULATE programme (SAS Software release
6.12; Cary, NC, 1989 to 1996).
The mean, standard deviation (SD), median, interquartile
range and the upper and lower quartiles were used for the
description of the numerical variables, using the SAS/
BASE PROC TABULATE programme.
Correlation among the different variables was determined
by Spearman's rank coefficient (considering the variables
as ordinal) and Pearson's coefficient (considering the var-
iables as quantitative). A comparison between NAWM
area in MS patients and controls and between White Mat-
ter Lesion (WML) and NAWM within the patient group
was performed.
To calculate the degree of association and agreement
amongst the main indexes of functional capacity and
magnetic resonance, the variables were divided and the
median was taken as a reference. The Chi-squared test was
then applied.
Consistency of the internal measurements was deter-
mined by dividing the total patient sample into two sub-
samples, each with half of the patients.
Results
Subject demographics and clinical parameters
Table 1 reports the demographics and clinical characteris-
tics of the MS Patients. The mean number of relapses in
the previous two years was 2.6 ± 0.6 (range 2–5).
The healthy control group was made up of 10 patients (5
male and 5 female) with a mean age of 42.5 years ± 24
years (median 42, range 14 – 74).
Tissue metabolite ratio
Table 2 shows the metabolite value of control subjects and
MS patients (in NAWM and in WML). MS patients
showed lower values of NAA compared with the controls.
No significant differences were found between the NAA,
Cr, Cho peak signal intensities of patients and control
subjects. Table 2 shows the metabolite ratio of control
subjects and MS patients (in NAWM and in WML). The
reduction of NAA in MS patients without significant
differences in Cr induced lower NAA/Cr in patients thanPage 3 of 10
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between the Cho/Cr metabolite ratio in WML and
NAWM.
Correlation between tissue metabolite concentration and 
clinical parameters
The objective of the study was to determine the correla-
tion among the different disability indexes and the NAA/
Cr ratio, in order to ascertain if this technique is a good
disability marker.
There is a clear correlation between the EDSS and NRS dis-
ability scores, the correlation coefficient (r) being -0.79 (p
< 0.0001). A clear correlation between the EDSS and AI
scores (r = 0.55; p < 0.001) and between the NRS and the
AI scores (r = 0.63; p < 0.0001) was also found. Evaluation
of other correlations amongst the EDSS, NRS and AI disa-
bility tests with the MSFC are given in Table 3.
There is a correlation among the two H-MRS values,
NAWM and White Matter Lesion (the correlation coeffi-
cient (r) is 0.47, p < 0.01). However the correlation
between the EDSS and the H-MRS in NAWM value was
low (r = -0.3; p = 0.056). This latter correlation was calcu-
lated using Pearson's test which is more sensitive than the
former one. The coefficient was -0.38 (p < 0.03) which is
statistically significant. We did not find correlation among
the two NAA/Cr values, in NAWM and in WML, with the
others disability scales.
Correlations between metabolite ratio and measures of
disability were significant too for NAWM mI/Cr with NRS
(r = -0.468; p = 0.007), NAWM mI/Cr with AI (r = 0.439;
p = 0.01), WML Cho/Cr with EDSS (r = -0.4, p = 0.02),
WML Cho/Cr with NRS (r = 0.37, p = 0.04) and WML
Cho/Cr with AI (r = -0.42, p = 0.01). We have found as
well a non linear correlation between metabolite ratio and
MSFC score: NAWM mI/Cr with TWT (r = -0.72, p =
0.0001, cubic correlation), NAWM mI/Cr with 9 HPT (r =
-0.51, p = 0.01, cubic correlation), NAWM Cho/Cr with
TWT (r = 0.42, p = 0.02, inverse correlation).
Internal consistency of measurements
To ensure the internal consistency of the measurements
the patient samples were sub-divided and the stability of
the parameters that determine the measurements was
checked. It was found that on dividing the samples both
Table 1: Clinical data of all patients with multiple sclerosis
Mean SD8 Median Min Max
Age (years) 38.6 8.4 32 18 48
Disease duration (years) 6.5 6 4 1 19
EDSS1 2.2 0.9 2 1 5.5
NRS2 90,0 6,8 92 72 99
AI3 1.52 1.3 1 0 4.5
MSFC 4 0.22 0.6 0.18 -1.3 1.48
TWT 5 0.37 0.1 0.40 -0.11 0.56
9 HPT 6 0.4 1.3 0.06 -2.04 3.02
PASAT 7 -0.11 0.9 -0.002 -1.74 1.24
Outbreaks 2.57 0.8 2 2 5
1 EDSS: Expanded Disability Status Scale 2 NRS: Neurological Rating Scale 3AI: Ambulation index 4 MSFC: Multiple Sclerosis Functional Composite 
5 TWT: 25 foot timed walk test 6 9 HPT: nine hole peg test 7 PASAT: paced auditory serial addition test 8 SD: Standard Deviation
Table 2: Proton magnetic resonance spectroscopic imaging voxel metabolite value and metabolite ratio (Mean +/- SD) of control 
subjects and patients with multiple sclerosis (NAWM vs. Control and WML vs. Control p > 0.05; * p < 0.05 vs. NAWM)
value Control NAWM WM lesion
NAA 106.1 +/- 20.9 102.23 +/- 20.2 102.61 +/- 29.9
Cr 61.7 +/- 13.0 62.13 +/- 14.2 63.94 +/- 13.0
mI 36.67 +/- 4.9 39.32 +/- 10.9 39.39 +/- 8.3
Cho 53.6 +/- 17.0 54.77 +/- 16.5 51.06 +/- 13.1
NAA/Cr 1.73 +/- 0.24 1.67 +/- 0.18 1.6 +/- 0.22
Cho/Cr 0.86 +/- 0.11 0.89 +/- 0.19 0.80 +/- 0.15*
mI/Cr 0.61 +/- 0.11 0.63 +/- 0.10 0.62 +/- 0.12
NAA: N acetylaspartate; Cr: Creatine; mI: Myoinositol; Cho: choline; NAWM: normal appearing white matter; WML: white matter lesionsPage 5 of 10
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fore vary with respect to the overall mean.
The mean and median H-MRS values were very similar,
which leads us to believe that this is a stable
measurement.
Discussion
This study demonstrates that patients' disability correlates
with levels of NAA, a marker of axonal loss. However, this
correlation is only seen when the EDSS but not the MSFC
is used. We have found significant correlations between
myoinositol (a gliosis marker) with NRS, AI and MSFC
score (TWT, 9 HPT). Our data also shows that there is a
weak correlation among the different disability scales
studied, as also occurs among the values measured with
H-MRS.
Markers of axonal loss and gliosis
In our study we found that, from the early stages of the
disease, NAA:Cr ratios determined by H-MRS, in NAWM
(1.67 ± 0.18) and White Matter Lesions (1.60 ± 0.22) were
lower in MS subjects than in healthy controls. These
results coincide with others published earlier, using simi-
lar techniques [50-54].
Since it was first described, MS has been considered a
demyelinating disease of the central nervous system, and
until recently axonal loss had not been studied in depth.
The N-Acetyl Aspartate levels detected by H-MRS could
provide a precise marker of axonal loss. [30-32,55-58]
Although the function of myoinositol (mI) is uncertain,
we know that it is involved in the polyphosphoinositol
second messenger cascade [71] and that it is relatively
concentrated in glial cells when compared with neurones
as was shown by multinuclear spectroscopy techniques
performed in rats [40,52]. So an increase in mI may reflect
neuroglial homeostasis and gliosis. [52]
Clinical outcome and H-MRS parameters
It has been suggested by various authors who have used
H-MRS [33,35,65-67] that the weakness of correlations
between MRI lesions and disability was due to abnormal-
ities in the NAWM. In a longitudinal study in 11 RRMS
patients, De Stefano and colleagues [9,68] demonstrated
a significant correlation between changes in NAA/Cr ratio
in NAWM and changes in disability score (measured by
EDSS), concluding that axonal damage in NAWM is
important in the understanding of chronic disability in
MS. Twenty nine patients with MS, 18 with secondary pro-
gressive MS and 11 with RRMS (EDSS: median of 5, range
3–6.5) were included in this study. Unlike the De Stefano
et al. study we did not evaluate the change in EDSS but the
baseline EDSS in patients whose disease was less devel-
oped and in a more uniform patient group. Our study
included 31 patients with RRMS with a lower EDSS
(median = 2, range of 1–5.5) and a short disease duration
(median 4 years). This leads us to believe that perhaps an
NAA decrease already exists in normal appearing white
matter since early stages of the disease.
In our study the correlation between NAA/Cr in NAWM
and EDSS was found to be statistically significant (r = -
0.38 (p < 0.03)). Tourbah et al [52] found a negative and
significant correlation between NAA/Cr in NAWM and
EDSS (r = -0.39). Davie [43] found a correlation of r =
0.364 in lesions in MS patients. De Stefano et al [59], and
Mainero et al [69] found similar correlations in recent
studies (r = -0.5), and this latter author point out that it is
the best correlation found in multiparametric MRI. They
Table 3: Correlations between the EDSS, AI disability tests and NRS with the MSFC score.
Spearman's (r) Correlation P value Pearson's (r) Correlation P value
EDSS vs TWT -0.9373 0.0269 -0.32376 0.0756
EDSS vs 9 hpt -0.31718 0.0821 -0.27393 0.1359
EDSS vs pasat -0.00863 0.9633 -0.00257 0.9891
NRS vs TWT 0.42254 0.0179 0.59967 0.0004
NRS vs 9 hpt 0.49227 0.0049 0.54910 0.0014
NRS vs pasat 0.09593 0.6077 0.19549 0.2919
AI vs TWT -0.56977 0.0008 -0.60091 0.0004
AI vs 9 hpt -0.62791 0.0002 -0.65049 <0.0001
AI vs pasat -0.07137 0.7028 -0.13566 0.4668
pasat vs TWT 0.23487 0.2035
pasat vs 9 hpt 0.23715 0.1990
9 hpt vs TWT 0.58846 0.0005
EDSS: Expanded Disability Scale Score; NRS; Neurological Rating Scale; AI: Ambulation Index; TWT: 25 foot timed walk test; 9 HPT: nine hole peg 
test; PASAT: paced auditory serial addition testPage 6 of 10
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is which best correlates with the Kurtzke EDSS.
Bonneville et al [70] did not report this correlation
between NAA levels and EDSS. However, they used an
overall NAA measurement that does not distinguish
between NAWM and T1 and T2-weighted lesion volumes.
This supports the theory that NAA behaves differently in
damaged areas in T2 and T1 probably because they
include areas with demyelination and remyelination
inflammation in which NAA recovery is possible (Table
4).
Discrepancy among the results of H-MRS studies in MS
could be due to the different patient selection and inclu-
sion criteria, the different techniques used, the different
area selected and the difference in the size of selected vol-
ume of interest [71].
What it is new in our study is that it was designed to meas-
ure axonal loss in relation to a multidimensional measure
of disability (MSFC), and it showed no correlations
between axonal damage (measured by NAA/Cr ratio) and
the MSFC in patients in early stages of the disease. This
suggests that the MSFC, which measures disability, is
more closely associated with MRI markers that measure
global disease burden, lesion burden and gliosis than with
axonal loss. Thus, we agree with Kalkers et al [72] that a
major part of the variability in the MSFC still remains uni-
dentified. In this article, Kalkers et al found no significant
correlation between ventricular fraction (VF) of MS
patients with short disease duration (≤5 years) and MSFC.
The relationship between clinical disability and NAWM
mI implies that glial proliferation in NAWM is associated
with a negative effect on clinical function (either NRS or
AI or MSFC (TWT, 9 HPT)) something we have not found
between clinical disability and WML mI. All these findings
support the idea that glial proliferation, or another path-
ological process leading to it, has a significant role in dis-
ability [40].
Study limitations
In this study H-MRS results are expressed as NAA/Cr ratio.
The resonance intensity of intravoxel Cr has been widely
used as an internal standard in H-MRS studies in vivo, as it
is relatively equally present in all brain cells and tends to
be stable in non-acute pathology [33]. We agree with
Arnold et al [59] that though changes in apparent brain Cr
levels have been reported in MS in recent H-MRS studies
attempting absolute quantitation, all current quantitative
approaches have considerable limitations when applied
to clinical studies. Discrepancies are found in the results
of studies in MS patients which report increases, decreases
and absence of Cr changes in MRI lesions and NAWM
[35,43,60-63]. A study using high resolution H-MRS in
vitro, which does not suffer from the limitations of in vivo
quantification, has demonstrated that Cr does not change
in normal appearing tissue of the brains of MS patients
[64]
Because of the short duration of the disease (median 4
years) and the low lesional load in T2 of our patients it
was impossible to choose large T2 weighted lesions with-
out NAWM included in the VOI to minimise the partial
volume effects. This is the reason why the mean NAA/Cr
ratio of T2 Weighted Lesions is close to the mean NAA/Cr
ratio in NAWM.
Conclusions
In conclusion, Magnetic Resonance Spectroscopy is a tool
that may play an important part in studies on natural his-
Table 4: Clinical outcome and H – MRS parameters: correlation EDSS – NAA. There is no data about NAA and other disability scales.
ARTICLE N MS COURSE CORRELATION 
WITH EDSS
SIGN VOI Loc
Fu L [9] 11 RR - <0.005 NAWM
18 SP - >0.05 NAWM
Tourbach [52] 55 RR + SP -0.39 0.003 NAWM
49 RR + SP -0.38 0.008 Lesions
Davie [32] 31 RR + SP + PP -0.36 0.05 – 0.02 Lesions
Mainero [69] 21 RR -0.5 0.01 NAWM
De Stefano [59] 88 RR + SP -0.55 <0.001 NAWM
55 RR -0.64 <0.001 NAWM
33 SP -0.28 <0.1 NAWM
Boneville [70] 49 RR - >0.05 WNAA
Izquierdo 31 RR -0.38 <0.03 NAWM
NAWM: normal appearing white matter; Lesions: white matter lesion; WNAA: Whole NAAPage 7 of 10
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sive or immunomodulatory treatment in clinical trials
[42,73]. It provides important data on axonal degenera-
tion which is the subject of this study. We have clearly
demonstrated a correlation between an MRS measure and
EDSS. EDSS seems to reflect the existence of irreversible
disability probably related to axonal degeneration,
whereas the MSFC does not appear to do so. MSFC is
probably a more sensitive measure of both global disease
burden and lesion burden than axonal loss. This will have
to be determined in longitudinal studies.
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